Sporotrichosis: A Comprehensive Review on Epidemiology, Clinical and Treatment of an Emerging Mycosis
Main Article Content
Abstract
Sporotrichosis is an emerging subcutaneous mycosis caused by the fungus Sporothrix schenckii. In this article, a comprehensive review of the epidemiology, clinical and treatment of this disease is presented. Relevant aspects of its geographical distribution, risk factors, zoonotic transmission and epidemic outbreaks are discussed. In addition, the clinical variability of sporotrichosis is analyzed in detail, describing its various forms of presentation, including cutaneous, lymphangitic and systemic.
Diagnostic challenges associated with its similarity to other mycoses and skin diseases are highlighted, and guidelines for its microbiological diagnosis are provided. Therapeutic options are also discussed, with emphasis on the use of systemic antifungals and the consideration of surgical treatment in selected cases. Finally, the importance of comprehensive knowledge of sporotrichosis to improve early detection, effective clinical management and prevention of complications in patients affected by this fungal infection is highlighted.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol 2005; 53(6):931-51.
II. Da Rosa AC, Scroferneker ML, Vettorato R, Gervini RL, Vettorato G, WeberEpidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad.Dermatol 2005; 52:451-9.
III. Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: Description of anarea of hyperendemicity. Clin Infect Dis 2000; 30(1): 65-70.
IV. Lyon GM, Zurita S, Casquero J, et al. Population-based surveillance and acase-control study of risk factors for endemic lymphocutaneous sporotrichosisin Peru. Clin Infect Dis 2003; 36(1):34-9.
V. Morris-Jones R. Sporotrichosis. Clin Exp Dermatol 2002; 27(6):427-31.Xue S, Gu R, Wu T, Zhang M, Wang X. Oral potassium iodide for the treatmentof sporotrichosis. Cochrane Database Syst Rev 2009; (4):CD006136.
VI. Tomersey L, de Moura L. Fixed cutaneous sporotrichosis. J Am Acad Dermatol 2007; 56(2) supplement 2:AB129.
VII. Nakagawa T, Sasaki M, Ishihama Y, Takaiwa T. Reinfection with lymphocutaneous sporotrichosis. Br J Dermatol 1997; 137(5):834-5.
VIII. Kayal JD, McCall CO. Sporotrichoid cutaneous Mycobacterium avium complex.infection. J Am Acad Dermatol 2002; 47(5):S249-50.
IX. Gezuele E, Conti-Díaz IA, Burgoa F, DeJiménez AC. Acute lymphangitic nocardiasis. Br J Dermatol 1973; 89(3):305-7.
X. Gerdsen R, Uerlich M, De Hoog GS, Bieber T, Horré R. Sporotrichoid phaeohyphomycosis due to Alternaria infectoria. Br J Dermatol 2001; 145(3):484-6.
XI. Gezuele E, Da Rosa D. Relevance of the sporotrichotic asteroid body in therapid diagnosis of sporotrichosis. Rev Iberoam Micol 2005; 22(3):147-50.
XII. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious
XIII. Diseases Society of America. Clin Infect Dis 2007; 45(10):1255-65.
XIV. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4):684-7.
XV. Francesconi G, Valle AC, Passos S, Reis R, Galhardo MC. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol 2009; 23(11):1273-6.